Skip directly to content

Houston EtE Plan Timeline

on Mon, 12/04/2017 - 14:47

Step-by-step progress of the Houston End the Epidemic plan 

Monday, December 4, 2017

By Tim Horn

Arguments favoring universal health care (UHC) are easy. Achieving political consensus as to the best strategy to achieve this is considerably more vexing. This is particularly true in the U.S., where the Affordable Care Act (ACA) patchwork of legislation and regulations has faced a barrage of executive and legislative attacks since the beginning of the year. And although the ACA and expansion of Medicaid in 32 states represents the closest the U.S.

How U.S. southern states are moving ahead without full health care coverage

By Jeremiah Johnson & Kenyon Farrow

Activists and health departments around the country continue to advance strategies to ‘End the Epidemic’ (EtE) in their jurisdictions, yet a central question remains. Are these ambitious plans appropriate in all U.S. jurisdictions, particularly given uneven access to health care systems?

What does the research tell us? 

By Richard Jefferys

After a long period during which HIV incidence rates seemed distressingly immutable, the last few years have seen a rapid accumulation of evidence that pre-exposure prophylaxis (PrEP) and HIV viral load suppression by antiretroviral therapy (ART) can dramatically reduce transmission risk. The effects of these interventions are now beginning to manifest at the population level, with reports emerging of declining HIV incidence in a number of different settings.

Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success

By Tim Horn

If there is one thing the majority of Americans agree on, it’s that health care costs—prescription drugs, in particular—are out of control and are significantly contributing to our broken health care system. Despite some campaign trail rhetoric that put the pharmaceutical industry on notice, the White House has yet to announce a bold agenda for curtailing egregious drug pricing.

Claiming and strategizing the HIV community’s role in universal health care advocacy

By Suraj Madoori and Maximillian Boykin

Perhaps the most impressive narrative in the lead-up to the dramatic defeats of the disastrous Affordable Care Act (ACA) repeal-and-replace bills in the House and Senate involved the thousands of activists who were activated, organized, and mobilized in an effort save U.S. health care.

Globalizing the insurance model will harm global public health

By Annette Gaudino

In the New York City of the 1850s, firefighting was a private enterprise. Homeowners and landlords purchased insurance plans that included protection from a dedicated fire brigade. When a fire broke out, brigades would arrive on the scene and look for an insurance company seal on the building. No hoses would be turned on until insurance coverage was verified. Often the building would have no seal, as fire insurance was not required.


At the World Hepatitis Summit in São Paulo, Brazil, held November 1-3, 2017, a large coalition of hepatitis patients, representatives of the drug using community, medical providers, researchers, and public health experts expressed their whole-hearted support to the commitment of the World Health Organization (WHO)’s goal to eliminate viral hepatitis by 2030; and declared that this goal will only be achieved if people who use drugs have access to effective, affordable prevention and treatment programs.

People who inject drugs are

Suboptimal Immune Recovery on Antiretroviral Therapy: Causes, Consequences, and the Search for Solutions

On November 29, 2017, Treatment Action Group (TAG) hosted a webinar on suboptimal immune recovery despite HIV suppression by antiretroviral therapy.

Presented by Richard Jefferys, TAG’s Basic Science, Vaccines and Cure Project Director, the webinar reviewed the possible causes and consequences of suboptimal immune recovery, as well as discussed the current lack of potential interventions to promote immune reconstitution in people with persistently low CD4 T cell counts despite HIV suppression.

Nelson Vergel from PoWeR described his own

Changing WHO Global TB Program Leadership

Statement from Mark Harrington, Executive Director
on Changing World Health Organization Global TB Program Leadership

1 December 2017

"On behalf of TAG, I congratulate Dr. Mario Raviglione on his retirement and thank him for his efforts and the years of collaboration while he was director of the World Health Organization’s (WHO's) Global TB Program. Though we didn't always agree, we shared mutual respect and the hope of catalyzing increased research and better programs for people affected by tuberculosis (TB).

Mario started as